Radius Health
950 Winter Street
Waltham
Massachusetts
02451
United States
Tel: 617-551-4000
Fax: 617-551-4701
Website: http://www.radiuspharm.com/
Email: info@radiuspharm.com
About Radius Health
Radius is a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases.Radius is committed to the research and development of new therapeutics for the large and underserved osteoporosis market.
YEAR FOUNDED:
October 3, 2003
LEADERSHIP:
Founders: John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt and John T. Potts
CEO: Robert Ward
CMO (Medical): Lorraine Fitzpatrick
CFO: Nick Harvey
CSO (Scientific): Gary Hattersley
JOBS:
Please click here for Radius Health job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
232 articles with Radius Health
-
Radius Health to Announce Third Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Monday, November 8, 2021
10/20/2021
Radius Health, Inc. (NASDAQ: RDUS) announced today that it will release its third quarter financial results on Monday, November 8, 2021.
-
Radius Announces Positive Phase 3 Topline Results for TYMLOS® (abaloparatide) Subcutaneous Injection in Males with Osteoporosis
10/18/2021
Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), today announced positive topline results from the ATOM study evaluating abaloparatide 80mcg subcutaneous (SC) for use in males with osteoporosis.
-
Celyad is focusing on advancing chimeric antigen receptor T cell (CAR T) therapies.
-
Radius Health Business Update - July 27, 2021
7/27/2021
New patient adds for the U.S. TYMLOS business continue to grow. New TYMLOS patients in Q2, 2021 were up over 40% vs. the same period in 2020.
-
Clinical Catch-Up: July 19-23
7/26/2021
It was another busy week for clinical trial updates. Here’s a look at some including Mesoblast Limited, CytoDyn, Magenta Therapeutics and more. -
Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study
7/22/2021
Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that it has recently received the written meeting minutes from a June Type C meeting held with the U.S. Food and Drug Administration (“FDA”) regarding RAD011, a synthetic cannabidiol oral solution.
-
Radius Health to Announce Second Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Thursday, August 5, 2021
7/20/2021
Radius Health, Inc. (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Thursday, August 5, 2021.
-
Radius Health, Inc.: First Quarter 2021 Results
5/7/2021
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial results for the first quarter ended March 31, 2021.
-
Radius Health Business Update
4/22/2021
Radius Health, Inc., provided the following business update. The Company’s first quarter 2021 earnings will take place on Friday, May 7 at 8:30am EST.
-
Radius Health to Announce First Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Friday, May 7, 2021
4/20/2021
Radius Health (Nasdaq: RDUS) announced today that it will release its first quarter financial results on Friday, May 7, 2021.
-
Radius Health Provides Update on Abaloparatide
3/24/2021
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided an update on the abaloparatide asset including regulatory progress as well as U.S. commercial activity.
-
Radius Health, Inc. Announces $175 Million Financing Transaction
3/3/2021
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today announced that the Company has entered into amended and restated credit facilities in the aggregate principal amount of $175 million, consisting of a $150 million term loan, which includes a cashless conversion of $25 million in existing term loans, and a $25 million revolving credit facility
-
Radius Health, Inc.: Fourth Quarter and Full Year Results - Feb 25, 2021
2/25/2021
Radius Health, Inc., reported its financial results for the fourth quarter ended December 31, 2020 as well as full year 2020 results.
-
Radius Health to Present at 10th Annual SVB Leerink Global Healthcare Conference
2/17/2021
Radius Health, Inc., announced that it will provide a corporate update at the 10th Annual SVB Leerink Global Healthcare Conference at 10:40 a.m. ET on Thursday, February 25, 2021.
-
Radius Health to Announce Fourth Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Thursday, February 25, 2021
2/16/2021
Radius Health (Nasdaq: RDUS) announced today that it will release its fourth quarter financial results on Thursday, February 25, 2021. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and provide a company update.
-
Radius Health, Inc. Announces Acquisition of Orphan Disease Program
1/6/2021
RAD011 is a pivotal-trial ready synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases
-
Radius Health, Inc. Provides Business Update
12/15/2020
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a general business update on progress made since October 2020.
-
Radius Health, Inc.: Third Quarter 2020 Operating Results
11/5/2020
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial and operating results for the third quarter ended September 30, 2020, and provided a business update.
-
Radius Health, Inc.: Progress Since May 2020
10/21/2020
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a general business update on progress made since May 2020.
-
BioSpace Movers & Shakers, Oct. 9
10/9/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.